MEK1 KO tumors displayed a growth‐impaired phenotype with T‐cell activation, and pharmacological MEKi reproduced tumor‐intrinsic effects but compromised T‐cell activation, confirming that T‐cell agonist therapy maximizes the beneficial effects of MEKi in counteracting the immune response to tumors.342. Here, MAP2K1 is linked to neoplasm.